Independent central review of progression in randomized phase II/III oncology trials: Is it needed?

Abstract

e16558 Background: Time to progression (TTP) or progression free survival (PFS) are increasingly being used as the primary endpoint for phase II/III trials in advanced disease trials in oncology. To minimize the potential bias introduced by subjectivity in radiographic interpretation, an independent review committee (IRC) has often been required in… (More)

Topics

  • Presentations referencing similar topics